Reuters logo
BRIEF-Aviragen Therapeutics to pay Vaxart $1.95 mln, if deal terminated
October 30, 2017 / 1:15 PM / 23 days ago

BRIEF-Aviragen Therapeutics to pay Vaxart $1.95 mln, if deal terminated

Oct 30 (Reuters) - Aviragen Therapeutics Inc

* On termination of merger under specified circumstances, co required to pay Vaxart termination fee of $1.95 million ​- SEC filing

* Anticipates incurring about $0.9 million-$1.7 million in total costs associated with job cuts related to Vaxart deal

* Company expects to incur the costs during next two quarters through March 31, 2018​ Source text for Eikon: (bit.ly/2yX5RQ3) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below